Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
Key Highlights
- ➤Seven abstracts accepted for ESGCT 2026 poster presentations
- ➤SGT-003 research covers DAPC stability and muscle integrity in Duchenne
- ➤POLARIS-101™ studies target antibody depletion and capsid transduction mechanisms
- ➤Three manufacturing studies address scalable AAV production, yield and quality
- ➤Presentations span gene therapy design, delivery, capsid engineering and manufacturing
CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that seven abstracts have been accepted for poster presentation at the 33(rd) European Society of Gene & Cell Therapy (ESGCT) Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.
The accepted abstracts span multiple areas of gene therapy research, including therapeutic design, next-generation delivery technologies, capsid engineering and manufacturing. The presentations include research supporting SGT-003, Solid's investigational Duchenne muscular dystrophy development program, evaluation of the Company's next-generation engineered myotropic POLARIS-101™ capsid platform and studies focused on improving rAAV manufacturing and vector performance. 1. Title: SGT-003 Gene Therapy Restores DAPC Stability and Improves Muscle Integrity in Duchenne Muscular Dystrophy Scientific Session: Cardiovascular & Muscular Diseases Poster Session: Poster Session I (Uneven Posters) Poster Number: P0611 Date/Time: October 28, 13:30-15:30 CET Presenter: Peter Burch, Director, Discovery & Translational Development
Get started
Create a free account to read the full story.